|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
Bioseeker, May 2011, Pages: 3,173
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Part II: Melanoma
The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
Part III: Protein Kinase Inhibitors
The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.
This part is based on the following publication:
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Customers who bought this item also bought
Triple Analysis: Lung Cancer, Lymphoma and Protein Kinase Inhibitors
Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors
Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors
Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors
Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Peptides
Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors
Triple Analysis: Colorectal Cancer, Lymphoma and Protein Kinase Inhibitors
Triple Analysis: Lymphoma, Prostate Cancer and Protein Kinase Inhibitors
|
|
|
|
